Note: Descriptions are shown in the official language in which they were submitted.
3L~383~75
BACKGROUND OF THE INVENTION
_ _
1. Field of the Invention
The novel synthetic organic compounds of the
present invention are antibacterial agents and are used
as are ot~ler members of that class.
2. Description of the Prior Art
Negamycin is an antibiotic discovered by the
present inventors (Japan 34827/1969, Japan 28835/1971)
and ls represented by the following ~ormula (III):
.
(R) (R) (III)
OH NH2 C~
having a unique structure consisting of a hydrazide bond
between (R,R)-~-hydroxy-~-lysine (IV) and l-methylhydra-
zinoacetic acid (V)
(R) (R)
H2NCH2fHCH2CIHCH2CE (IV) ~ ;
OH NH2
H2N7CH2COOH (V)
(J. Am. Chem. Soc. 93, 6305, 1971). In the above
formulae, a symbol (R) is indicated and used for stereo-
chemistry (Ref. "Nomenclature of Organic Compounds" ed.
by J. H. Fletcher, O. C. Dermer and R. B. Fox, p. 103,
American Chemical Society, Washington, D.C., 1974).
See also U.S. Patents 3,619,742 and 3,743,580 and M.
Hamada et al , A New Antibiotic, Negamycin, J. Antibiotics~
23(3), 170-71 (1970).
~83~ 5
SUMMARY OF TXE_INVENTION
The present invention provides new derivatives
of negam~cin, that is, semisynthetic antlbiotics having
the ability to inhibit Gram-positive and Gram-negative
bacteria and belng o~ qulte stable character even in acidic
aqueoUs solution~, which are represented by the ~ollowing
~ormula:
(R) (R) ~ :
H2NcH2fHcH2cHc~2coNHNc~2cooH (II)
D NH2 C~
and the acid and base salts thereo~, wherein D is selected
~rom the group consisting o~ H (deoxynegamycin) and C~ O-
(O-methylnegamycin).
The subject of this divisional application is a
process for the production of O-methylnegamycin having the
formula
(R) (R)
H2NcH2cHcH2fHcH2coNHNl cH2cooH ~`' . ,
OCH3 NH2 CH3 ~ .
which comprises the consecutive steps of
a) reacting diazomethane in the presence of
boron trifluoride etherate with a conventional, easily ;~ - .
removable ester of amino-protected negamycin to form the ;~
intermediate having the formula
A ~ (R) (R) :~ -
~NCH2IHCH2fHCH2COnHNCH2COOCH3 ' ,~
OCH3 N' CH : .
\ B 3 - : .~
wherein A is hydrogen and B is a monovalent amino-protective ~ ; ;
group or A together with B are a divalent amino-protective
group and
.
.... .
.. . . .
,
~831~
b) removing from said intermediate the amino-prOt~ctive
groups A and s and the methyl ester group to form
O-methylnegamycin.
Preferably in ~his process A i~ hydrogen and B is a
benzyloxycarbonyl group.
Also preferably in such a process the amino-protective
groups A and B and the methyl ester group are removed by
hydrolysis followed by column chromatography with cation
exchangers having carboxylic ~cid as the active group.
In one embodim~nt the invention provides such a process :
further comprising the step of forming a pharmaceutically
acceptable nontoxi~ salt or acid addition salt of
O-methylnegamycin. :-
Salts o~ deoxynegamycln and O-methylnegamycin
lnclude carboxylic acld salt~ lnclud1ng nontoxic metallic
salts such as sodl~m, potassium, calcium and aluminum, the . ~ :
ammonium salt and substituted ammonium salts, e.g. salts
o~ such nontoxic amines as trialkylamines, including tri~
ethylamine~ proc~ine, dibenzylamine, N-benzyl-~-phenethyl- `.
amine, l-ephenamine, N,N'-dibenzylethylenediamine, dehydro-
ab~etylamine, N,N'-bis-dehydroabietylethylenedi~mine, ;~
N-(lower)alkylpiperldine, e.g. N-ethylplperidine and .
other amines whlch have been used to form salts with ~
benzylpenlcillin; and the nontoxic, acid additlon ~alts .
thereof, (l.e. the amine salt~) including the mineral
acid addition 8alts such as the hydrochloride, hydrobro-
mide, hydrolodide, sulfate, ~ul~amate and phosphate and ~
the organlc acld addition salts such as the maleate, : ~ :
acetate, citrate, oxalate, succinate, ben~oate, tartrate~
fumarate, malate, m~ndelate, ascorbate and the like.
Also ~ncluded are t~ 8al~8 Or deo~ynegamgcln and ~ ~
.~ ~ ...
-3~
.-
.: . . . ,, :.
, .. . . . . .
33:~75
0-methylnegamycin with cinnamic acid, picric acid,
p hydroxyazobenzene-p'-sulfonic acid, phytic acid~
livopimaric-6,6a-cis-endosuccinic acid, sulfamic acid
and glycolic acid. For therapeutic purposes use is
made o~ salts o~ nontoxic acids but salts of toxic
acids, e.g. p-hydroxyazobenzene-p'-sulfonic acid, are
useful in isolation procedures, e.g. as precipitants
from aqueous solut~ons and for disinfectant purposes
where toxicity is not important.
In the treatment o~ bacterial infections in
animals, including man, the compounds of this invention
are administered parenterally in accordance with con-
ventional procedures for antibiotic administration in ~:
an amount of from about 5 to 200 mg./kg./day and pre-
ferably about 5 to 20 mg./kg./day in divided dosage,
e.g. three to four times a da~. They are administered
in dosage units containing, for example, 125 or 250 or
500 mg. of acti-~e ingredient with suitable physiologically
acceptable carriers or excipients. The dosage unit-s are
in the form of liquid preparations such as solutions or
suspensions.
The compounds of the present invention are also
used topically in the treatment of superficial lnfections
such as infections o~ skin or mucous membrane. For this
purpose use can be made of conventional ointments, (e.g.
1~ or 5~) or solutions and suspensions in aqueous media
at concentrations of 1~ to 10~.
The present invention provides the synthesis of
~-substituted negamycins which are much more stable in
aqueous solution than negamycin itself and have antibac-
.4.
,
33~75
terial activities. Thus, a constituent of negamycin,(R,R)-~-hydroxy-~-lysine (rV), is converted to D-~-lysine
by removing the hydroxyl group at ~-position or to (R,R~-
~-methoxy-~-lysine by replacing the hydroxyl group with a
methoxyl group at ~ position, and two amino groups in
those derlvatives are protected, the acid coupled with -
l-methylhydrazinoacetic acid and the protective groups ~or
the amino groups are then removed to yield the desired
~-subqtituted negamycin derivatives, deoxynegamycin or
O-methylnegamycin as shown as formula (II) which are
found to be quite stable in aqueous solutlon and active
against Gram-positive and Gram-negative bacteria. ;
In one aspect of the present invention
N~N'-di-protected-D-~-lysine (D - H in formula I) and
N,N'-di-protected-(R,R)-~-methoxy-~-lysine (D ~ -OCH~ in ~:
formula I), which are represented by the following
formula:
H21HCH21CHCH2COOH
D M ~
. B
wherein A is hydrogen and B is a monovalent protective
group for an amino group or A and B are one divalent
protective group for an amino group and D is hydrogen or
methoxyl, are separately coupled with 1-methylhydrazino- ;
acetic acid and the protective groups removed to prepare
deoxynega~ycin (D = H in formula II) or O-methylnegamycin
(D = -OCH3 ~n formula II).
1~l33~5
... ..
(R) (R)
H2NcH2cHcH2lHcH2coNHNcH2cooH (II)
D NH2 3
Starting materials (I'), D-~-lysine (D = H) and
(R,R)-~-methoxy-~-lysine (D - -OCH~
(R) (R)
~2NC~2lHCH2lHCH2COOH (I') ~ -
NH2
should be protected with known protective groups on the1r
two amino groups. Although use can be made of the usual
amino-protective groups used for peptide synthesis as the
known protective groups, the protective groups used should ~;~
be easily removed without any cleavage of hydrazide bond
in a compound which is synthesized from a ~-lysine deriva-
tive (I) and 1-methylhydrazinoacetic acid by this procedure.
Suitable monovalent protective groups for amino
groups in the ~-lysine derivative are alkyloxycarbonyl
groups, e.g. tert-butyloxycarbonyl group; cycloalkyloxy~
carbonyl groups, e.g. cyclohexyloxycarbonyl group; aryl~
alkyloxycarbonyl groups, e.g. benzyloxycarbonyl and
p-methoxylbenzyloxycarbonyl groups; and acyl groups
especially lower alkanoyl groups, e.g. trifluoroacetyl
and o-nitrophenoxyacetyl groups. A divalent protective ~ `;
group is a Schiff base such as salicylidene group. Those
protective groups are introduced by known procedure, e.g.
using acid halide, acid azide, active ester, etc. ~ ;
In the prepara-tion of deoxynegamycin the D~
lysine used as the starting material is made, for example
by the treatment of (R,R)-~-hydroxy-~-lysine with red
phosphorus and hydroiodic acid in a sealed tube at 150 C.
-6-
., . , .. .. ,. , .. .. . . : . -
~11 83~S
for 2 hours. The (R,R)-~-hydroxy-~-lysine is obtained by
hydrolysis of negamycin or by synthesis from D-galacturonic
acid (J. Am. Chem. Soc., 94, 4353, 1972). Amino-protective
g~oups are introduced into D-~-lysine as described above. -
For instance, by the treatment of D-~-lysine with benzyl
S-4,6-dimethylpyrimidin-2-ylthiolcarbonate in the presence
of triethylamine in water-dioxane solution, di-N-benzyloxy-
carbonyl-D-~-lysine is obtained at excellent yield.
In the preparation of O-methylnegamycin the
(R,R)-~-methoxy-~-lysine used as the starting material is
also synthesized from (R,R)-~-hydroxy-~-lysine and con-
verted directly to the di-N-benzyloxycarbonyl derivative
of (R,R)-~-methoxy-~-lysine. For instance, the aqueous
solution of (R,R)-~-hydroxy-~-lysine is treated with benzyl-
oxycarbonyl chloride in the presence of sodium bicarbonate
yielding a lactone of di-N-benzyloxycarbonyl-(R,R)-~-
hydroxy-~-lysine as crystals. The lactone is dissolved in
0.5%-hydrogen chloride in methanol, allowed to stand at
room te~perature and the reaction mixture is concentrated
to obtain the methyl ester of di-N-benzyloxycarbonyl-
(R,R)-~-hydroxy-~-lysine as crystals The ester is reacted
with diazomethane in the presence of boron trifluoride
etherate in dichloromethane followed by hydrolysis with
sodium hydroxide in ethanol to yield di-N-benzyloxycar-
bonyl-(R,R)-~-methoxy-~-lysine.
In the coupling process the condensation ~orming
a hydrazide bond with the N-protected ~-lysine derivative
(I) and l-methylhydrazinoacetic acid is carried out by
known methods for amide synthesis such as methods using
dicyclohexylcarbodiimide, mixed anhydride, azide, acid
halide, active ester, etc.
-7-
1(~83~5
For instance, the di-N benzyloxycarbonyl deriva-
tlve o~ the ~-substituted (R,R)-~-hydroxy-~-lyslne i8
converted to an active ester by treatment with N-hydroxy-
succinlmlde and dicyclohexylcarbodiimide in a nonaqueous
solvent. The active ester is condensed with 1-1.5 moles
of 1 methylhydrazinoacetic acid in the presence of 1-2.5
moles of sodium bicarbonate in an aqueous solvent. The
coupling product thus obtained is treated with 25~ hydro~
gen bromide in acetic acid or hydrogenated with platinum,
palladium, etc. as the catalyst to remove the N-benzyloxy-
carbonyl groups and to synthesize the desired products
(II), that is ~-substituted negamycins.
The removal of the protective groups from the
coupling product is carried out by a usual method as
described above. When the protective groups are alkyloxy-
carbonyl group or Schif~ base the coupling productæ are
hydrolyzed with a weak acid to remove the amino-protective
groups.
An arylalkyloxycarbonyl group as the protective
group is removed by the treatment with 25~ hydrogen bro~
mide in acetic acid, and o-nitrophenoxyacetyl group is
easily removed by catalytic hydrogenation with platinum,
palladium, etc.
The products are purified with good recovery
by ion exchange chromatography using carboxylic cation
exchange resins such as "Amberlite CG-50" (Rohm and Haas
Co. Ltd., U.S.A.) or "CM-Sephadex C 25" (Pharmacia,
Sweden).
0-Methylnegamycin and deoxynegamycin are also
able to be derived directly from an amino-protected
derivative of negamycin itself as shown in the following
*Trade Marks _8
~(~83~L~75
':
formula:
A~ (R) (R)
CH2fHCH2CHCH2CONHTCH2COOH (VI)
OH N 3
B
wherein A is H and B is a monovalent amino-protective
group or A together with B is one dlvalent amino-protective
group. As the amino-protective groups for negamycin, all
known amino-protective groups used for D-~-lysine or
(R,R)-~-methoxy-~-lysine above are available in the same
procedure For instance, negamycin is treated with benzyl
S-4,6-dimethylpyrimidin-2-ylthiolcarbonate in the presence
of triethylamine in a mixture of water-dioxane to obtain
di-N-benzyloxycarbonylnegamycin (A = H, B - COOCH2C6H5 in
~ormula VI) in high ~ield. m e benzyloxycarbonyl groups in
this derivative are removed by catalytic hydrogenation
simultaneously removing halogen atom to prepare deoxynega-
mycin as described later, and therefore this group is a
useful amino-protective group.
O-Methylnegamycin is synthesized from an amino~
protected derivative of negamycin (VI) by the same reaction `
conditions used for O-methylation of amino-protected ~ -
(R,R)-~-oxy-~-lysine, that is, treatment with diazomethane
in the presence of boron trifluoride etherate in an inert
organic solvent such as dlchloromethane to obtain an
amino-protected derivative of O-methylnegamycin methyl
ester as shown by the following formula:
A (R)
NCH CHCH CHCH CONHNCH COOCH (VII )
B ~ 21 21 2 1 2
~B CH~;
wherein A and B mean the same groups described above. The
1'7S
amino-protective group and methyl ester group are removed
by hydrolysis followed by col D chromatography wlth cation
exchangers having carboxylic acid as the active group,
and if necessary are purified by a column chromatography
on silica gel obtaining O-methylnegamycin as the final
product.
The present invention also provides -the process
for the preparation of O-methy~negamycin which comprises
conversion of amino-protected derivatives of negamycin (VI)
~NCH2CHCH2CHCH2CONHNCH2COOH (~
OH N~ C~
to amino-protected derivative of O-methylnegamycin methyl
ester (VII) by reaction with diazomethane in the presence
of boron trifluoride etherate followed by removal of the
amino-protected groups and methyl ester group from the
product (VII).
A~
NCH2CHCH2CHCH2CONHNCH2C~OCH~
OCH3 N~ CH3 ~.
In this procedure the reaction with diazomethane
is carried out in an inert organic solvent7for instance, ; ;
halogenated hydrocarbons such as dichloromethane. The
removal of the amino-protective groups and methyl ester
group is carried out by ordinary procedures, for instance~
by hydrolysis in alkaline condition.
Furthermore, in the synthesis of deoxynegamycln
from the amino-protected derivative of negamycin (VI), the
only free carboxyl group of amino-protected negamycin i~ `
primarily protected with a common ester form, for instance~
--10-- --
33~L7~i ~
methyl , ethyl or benzyl ester to obtain an ester of
amino-protected negamycin. And then the hydroxyl group
at the ~-position of the ester i8 sulfonylated by treat-
ment with alkylsulfonylating agent such as mesyl chloride,
arylsulfonating agent such as p-toluenesulfonyl chloride,
or arylmethylsulfonylating agent such as benzylsulfonyl
chloride to obtain the sulfonic acid ester derivative as
shown by ~III.
A~ (R) (R)
~NcH2cHcH2THcH2coNHlcH2coE (VIII)
S03G ~ CH3
wherein A and B are the same as described in the above;
E is an alkyloxy group especially consisting o~ 1-4 carbon
atoms or a benzyloxy group which are ester forming radi-
cals removable easily by hydrolysis to hydroxyl group; G
is an alkyl group and especially a lower alkyl group,
phenyl group or alkyl substituted phengl or benzyl group.
The product (VIII) is treated with an iodide or bromide of
alkaii metal such as sodium iodide or sodium bromide and
the sulfonyl ester at the ~-position is replaced with
iodine or bromine to obtain the ~-iodo- or ~-bromo-deriva-
tive which is a mixture o~ R and S at the ~-position. The
iodo- or bromo-derivative in water or methanol or mixed
solvent of water and methanol is hydrogenated with pal-
ladium or platinum as the catalyst to produce deoxynega-
mycin derivative by dehalogenation. When the amin ~
protected group is the benzyloxycarboxyl group as described
above the removal of the amino-protected group takes place
simultaneously in the above-mentioned catalytic hydrogena-
tion. The remaining amino-protected group is removed by
the procedure described above. The ester group of the
1~83~7S
product is removed by hydrolysis under weakly alkaline
conditions and the reaction mixture is purified by
column chromatography on cation exchange resin having
carboxylic acid as the active group to obtain deoxy-
negamycin as the final product.
There is further provided by the present inven-
tion the process for the preparation of deoxynegamycin
whereby an amino-protected derivative of ~-halogenated
negamycin ester (IX) is catalytically hydrogenated and
the remaining amino-protective group in the compound is
removed by a conventional method and the ester ~orming
group (E) is converted to hydroxyl by hydrolysis.
A~ (R)
NcH27HcH2THcH2coNH I CH2COE
X N CH
~ B 3
(wherein A is hydrogen and B is a monovalent amino-
protective group or A together with B is one divalent
amino-protective group, E is an ester forming group which
is converted to hydroxyl by hydrolysis, and X is iodine
or bromine atom.) ~-
The this procedure an amino-protected deriva~
tive of ~-halogenated negamycin ester (IX) is prepared
as follows. An amino-protected derivative of negamycin
(VI) prepared as above is treated with an agent for -
esterification such as diazomethane or diazoethane to
convert it to negamycin ester derivative (carboxylate).
Next the ~-hydroxyl group of the derivative is sulfonylated
(-S03G) and then halogenated. For instance, the sulfonyla-
tion is carried out according to a similar procedure used
to prepare an intermediate in the production of ~',4'-
-- 1~ _
~8317~
dideoxykanamycin B as described in Japan Patent 7595/1975.
The reaction to convert the sulfonyl group (-S03G) to
halogen group (X) by the effect of an iodide or bromide
of an alkall metal and the procedure to remove the
~-halogen group by catalytic hydrogenation is also
carried out in known manner.
The properties o~ deoxynegamycin and O-methyl-
negamycin which are the final products obtained in this
invention are as follows:
Deoxynegamycin is a white powder showing d.p.
120-125 C. [a]23 = 5o (c 1.5, H20) and elemental
analysis to coincide with the theoretical value for
CgH20N~03-H20 (C 43.18~, H 8.86%, N 22.39%). On silica
gel thin lajer chromatography (Art. 5721, Merck Co.,
Germany) de~eloped with n-butanol-ethanol-chloroform-17%
aqueous amm~nia (4:5:2:5 by volume) it gives a single
spot (ninhy_rin) at Rf 0.~4.
O-Methylnegamycin is a white powder showing
d.p. 137-140 C. ~a]22 = -3 (c 1.5, H~O), and elemental
~nalysis to coincide with the theoretical value for
CloH22N4C4 H20 (C 42.84~, H 8.63~, N 1~.99~). On the tlc
described above it gives a single spot at Rf 0.33. As
shown in the table, those two novel derivatives of nega
mycin inhibited the growth of Gram-positive and Gram-
negative bacteria. Those two compounds were completely
stable in both aqueous or 0.02N HCl aqueous solution at
37 C. for one month while negamycin as the control was
reduced in its activity to 63~ in aqueous solution and to
50~ in 0.02N HCl aqueous solution. Those two compounds
are low in to~icity (LD50 of both in mice, i.v., >200
mg./kg.) and are expected to be used in the chemotherapy
~aQ831~S
of infections caused by various Gram-positive and Gram-
negative bacteria.
TABLE: Antimicrobial Spectra of O-Methylnegamycin and
Deoxynegamycin
Min~mum Inhibi~ory
Concentrations*(Mcg./ml.)
O-Methyl-Deoxy-
Test Organisms _ ~Y~ æ~ YD5
StaPhylococcus aureus FDA209P 12.5 25
Staphylococcus aureus Smith 6. 256.25
Sarcina lutea PCI1001 25 ~100 ;
Micrococcus ~lavus FDA16 50 50
Bacillus subtilis NRRL B-5s8 50 100
Mycobacterium smegmatis ATCC607 25 50
Escherichia coli NIHJ 6 256. 25
. , ~
Escherichia coli K-12 3-13 3.13
Escherichia coli K-12 ML1629 1 56 3013
.
Salmonella t~phi T-63 1 - 56 o . 78
Proteus ulgaris OX-l9 1- 56 3.13
Proteus rett~eri GN311 6.25 6.25
Proteus rett~eri GN466 3.13 3.13
Serratia marcescens 25 25
Klebsiella pneumoniae PCI602 6.25 6.25
Pseudomonas :~luore~cens 1- 56 3-13
Pseudomonas aeruginosa A3 12.5 25 ~i
Pseudomonas aeruginosa No. 12 25 50
. .
.. _ ._
*Minimum inhibitory concentrations were determined on a
0.5% peptone agar by incubatlon at 37 C. for 17 hours.
- 1~
10831~5
DESCRIPTION _F THE PREFE _ED EMBODIMENTS
EXAMPLE 1
(a) Synthesis of Di-N-benzyloxycarbon~vl-D-~-lysine-
.
To ~ solution containing 100 mg. (o.6g mmolej
D-~-lysine ([~]25 = -22.5 (c o.8, lN HC1) in 1 ml. of
water, 104 mg. (1.0 mmole) of triethylamine at first
and then a solution containing 410 mg. (1.5 mmoles)
benzyl S-4,6-dimethylpyrimidin-2-ylthiolcarbonate
(Kokusan Chemical Works~ Tokyo) in 1 ml. o~ dioxane were
added and stirred at 30 C. for 17 hours. To the
reaction mixture 3 ml. of water was added and the mix-
ture was washed with 6 ml. of ether. The aqueous layer
was adjusted to pH 2 with 6N HCl, saturated with sodium
chloride and extracted with 13 ml. of ethyl acetate. The
ethyl acetate layer was washed with 4 ml. o~ 5% HCl in
water saturated with sodlum chloride and with 4 ml. of
water saturated with sodium chloride, dried with anhydrous -
sodium sulfate and concentrated to dryness under reduced
pressure to obtain 219 mg. of di-N-benzyloxycarbonyl-D-
~-lysine as colorless crystals, d.p. 149-151 C`., [a]D6 =
l6 (c 1.3, MeOH), 73~ yield.
(bj Synthesis of Deoxynegamycin~
To a solution containing 79 mg. of di-N-benzyl-
oxycarbonyl-D-~-lysine obtained in Example 1 (a) dissolved
in 3 ml. of 1,2-dimethoxyethane, 22 mg. (0.19 mmole) of
N-hydroxysuccinimide and 39 mg. (0.19 mmole) of dicyclo-
hexylcarbodiimide were added under ice-cooling. After
the reaction mixture was allowed to stand at 5 C. for 17
hours crystals of dicyclohexylurea deposited and were
removed by filtration and the filtrate was concentrated
3L~83:~L75
to dryness to obtaln 97 mg. of N-hydroxysuccinimide
ester of di-N-benzyloxycarbonyl-D-~-lysine as colorless
crystals.
A solution containing the crystals obtained in
the above dissolved in 2 ml. of 1~2-dimethoxyethane was
gradually added to a solution containing 19.8 mg. (0.19
mmole) of l-~methylhydrazinoacetic acid and 32 mg. (o.~8
mmole) of sodium bicarbonate in 0.5 ml. of water under
stirring at room temperature. After 18 hour~ stirring
the reaction mixture was concentrated to dryness under
reduced pressure and the residue was dissolved in 0.5
ml. of water. To this solution cooled in ice was added
0.42 ml. of lN HCl forming a white precipitate. The
precipitate was collected by filtration, washed with
water and dried to obtain 108 mg~ of di-N~benzyloxycar-
bonyldeoxynegamycin as a white powder.
The white powder was dissolved in a mixture
containing 1 ml. of acetic acid, 0.8 ml. methanol and
0.2 ml. water. To the solution was added 50 mg. of 5
palladium-carbon. After the mixture was stirred for 3
hours under an atmosphere of hydrogen the catalyst was
removed by filtration and the filtrate was concentrated
to dryness. The residue was dissolved in 2 ml. of
water adjusted to pH 8.4 with 5N ammonia-water and
passed through and adsorbed on a column containing 8.5
ml. Am~erlite CG-50 (NH4 ) resin. The column was washed ?
with 20 ml. water and eluted with 90 ml. of 1~ ammonia--
water. The eluate was collected as 1 ml. fractions.
Fractions No. 57-62 having antibacterial activity to E.
coli K-12 were collected and concentrated to dryness to
obtain 20.5 mg. of deoxynegamycin as a white powder.
Yield was 47~. _
16 ~
.
1~83~
EXAMPLE 2
(a) Synthesis of Di-N-benzyloxycarbonyl-(R,R)-~-hydroxy-
~-lysine Meth~l Ester:
To a solution containing 26 g. of (R,R)-~-hydroxy-
~-lysine and 63 g. of sodium bicarbonate in 450 ml. of
water was added dropwise 77 g. o~ benzyloxycarbonyl
chloride at room temperature. After stirring for another
2 hours the mixture was allowed to stand at 5 C. for 1
hours. Crystals deposited and were collected by filtra-
tion, washed with 200 ml. of water and with 350 ml. of
ether and dried to obtain 44.~g. of di-N-benzyloxycarbonyl-
(R,R)-~-hydroxy-~-lysine lactone as colorless crystals.
m.p. 128-130 C., [a]D2 = -13 (c 3.4, chloroform), 70%
yield. m e crystals (~4.2 g.) were dissolved in ~60 ml.
of 0.5% HCl-CH30H and allowed to stand at room tempera-
ture for 16 hours. The reaction mixture was concentrated
and the crystals which deposited were recrystallized from
a mixture of methanol-ether to obtain 28.3 g. of di-N-
benzyloxycarbonyl-(R,R)-~-hydroxy-~-lysine methyl ester
as colorless crystals. m.p. 111 112 C ~ [a]D8 = +11
(c 1.2, chlorofo ~, 77% yield.
(b) Synthesis of Di-N-benzyloxycarbonyl-(R~R)-~-methoxy-
~-lysine:
The 266 mg. (o.6 mmole) of di-N-benzyloxycar-
bonyl-(R,R)-~-hydroxy-~-lysine methyl ester obtained in
Example 2 (a) was dissolved in 4 ml. of dichloromethane
To that solution under stirring at ice-cooling was added
17 mg. (0.12 mmole) of boron trifluoride etherate and to
the mixture 1.5% diazomethane-ether was added until the
yellow color remained in the reaction mixture (4 hours).
~83~L~S
After stirring at room temperature for 16 hours the
reaction mixture was washed with 10 ml. of 10~ sodium
bicarbonate-water and 20 ml. of water successively and
the solvent layer was dehydrated with anhydrous sodium
sul~ate and concentrated to dryness under reduced pres-
sure yielding 295 mg. of a pale yellow oily material.
The olly material was chromatographed on a column con
taining 30 g. of silica gel developed with benzene-
methyl ethyl ketone (10:1 by volume) and collected in
9 ml. ~ractions. FractionSNo. 31-59 were collected and
concentrated to dryness yielding 87 mg. of di-N-benzyl-
oxycarbonyl-(R~R)~~-methoxy-~-lysine methyl ester as a
colorless oil. 32% yield.
To a solution containing 85 mg. (0.19 mmole)
of the oil in 0.5 ml. of ethanol~O.22 ml. of lN NaOH was
added. After allowing to stand at room temperature ~or
4 hours the mixture was acidified by the addition of
0.28 ml. o~ lN HCl and extracted with ~ ml. of ethyl
acetate. The ethyl acetate layer was washed with 1
ml. of water, dehydrated with anhydrous sodium sul~ate
and concentrated to dryness yielding 80 mg. of di-N-
benzyloxycarbonyl-(RgR)-~-methoxy-~-lysine as a color- ?
less oil. 98% yield.
(c) Synthesis of O-Methylnegamycin:
To a solution containing 80 mg. (0.18 mmole)
o~ di-N-benzyloxycarbonyl-(R,R)-~-methoxy-~-lysine
which was obtained in Example 2 (b), in 1.6 ml. of
1,2-dimethoxyethane, 21 mg. (0.18 mmole) o~ N-hydroxy-
succinimide were added under ice cooling. A~ter the
reaction mixture was allowed to stand at 5 C. for 17
-18-
~33~S
hours dicyclohexylurea appeared and was removed by
filtration and the filtrate was concentrated to dryness
yielding 98 mg. of N-hydroxy succinimide ester of di-N-
benzyloxycarbonyl-~R,R)-~-methoxy-~-lysine as a color-
les~ oil.
A solution of the oil in 1.5 ml. of 1~2-
dimethoxyethane was gradually added at room temperature
under stirring to a solution containing 18.7 mg. (0.18
mmole) o~ l-methylhydrazinoacetic acid and 30 mg. (o.~6
mmole) of sodium bicarbonate in 0.5 ml. of water. After
stirring for 20 hours the reaction mixture was concen-
trated to dryness, dissolved in 0.5 ml. of water and a
white powder was precipitated by the addition of 0.4 ml.
lN HCl under ice-cooling. The precipitate was dissolved
in 3 ml. of ethyl acetate and washed with 0.5 ml. of
water. The ethyl acetate layer was dehydrated with anhy-
drous sodium sulfate and concentrated to dryness yielding
94 mg. of di-N-benzyloxycarbonyl-0-methylnegamycin as a
white powder.
To a solution containing the white powder ob-
tained above in a mixture containing 1 ml. of acetic
acid, o.8 ml. of methanol and 0.2 ml. of water, 24 mg.
of 5~ palladium-carbon was added and the mixture was
stirred with hydrogen gas for 4 hours. After removal
of catalyst by filtration the filtrate was concentrated
to dryness. The residue was dissolved in 2 ml. of
water,adjusted to pH 8.8 with 5N ammonia and charged
into a column containing 10 ml. of Amberlite CG-50
(NH4 ). The column was washed with 20 ml. of water and
eluted with 100 ml. of 0.1~ ammonia-water collecting
1 ml. fractions. Fractions No. 45-57 having antibacterial
_ 19_
. .
31331~5
activity were combined and concentrated under reduced
pressure to dryness to provide 20 8 mg. of 0-methyl-
negamycin as a white powder. 44% yield.
EXAM LE 3
(a) S~nthesis o~ Di-N-benzyloxycarbonylnegamycin:
To a solution containing 4 g (16.1 mmoles) of
negamycin in 20 ml. of water and 2.44 g. (24.2 mmoles)
of triethylamine, 9.72 g~ (35.5 mmoles) of benzyl S-4,6-
dimethylpyrimidin-2-ylthiolcarbonate in 20 ml. o~ dioxane
was added and the reaction mixture was stirred at room
temperature for 17 hours. To the reaction mixture 30 ml. of
water was added and the mixture was washed with two por-
tions of 60 ml. of ethyl acetate. The aqueous layer was
ad~usted to pH 2 with 6N HCl and extracted with two por-
tions of 60 ml. of ethyl acetate after saturation with
sodium chloride. The ethyl acetate layer was washed with
80 ml. o~ water saturated with sodium chloride dehydrated
with anhydrous sodium sulfate and concentrated to dryness
under reduced pressure to yield 7.6 g of di N-benzyl-
oxycarbonylnegamycin as a white powder. d.p. 110-113 C.,
[a]25 = +4.2 (c 6.3, CH30H), 92% yield.
(b) Synthesis of 0-Methylnegamycin
.
To a solution containing 449 mg (0.87 mmole)
of di-N-benzyloxycarbonylneg~mycin which was obtained in
Example 3(a), in 405 ml. of dichloromethane, 62 mg.
(0.44 mmole) of boron trifluoride etherate was added
with ice-cooling and stirring followed by the addition
of 1.5~ diazomethane-ether solution until the yellow color
_20_
~83~75
of the reaction mixture remained (for two hours). The
reaction mixture was concentrated to dryness yielding
di~N-benzyloxycarbonyl-0-methylnegamycin methyl ester as a
crude powder. The powder was dissolved in 5 ml. of 25~
hydrogen bromide-acetic acid and stirred at room tempera-
ture for 20 minutes to remove the amino-protective groups.
To the solution 50 ml. of ethyl ether was added
and a precipitate appeared which was collected by fil-
tration, washed with 20 ml. o~ ethyl ether and dried to
obtain a yellow powder. The powder was dissolved with
20 ml. o~ water, ad~usted to pH 8.8-9.o with 5N ammonia-
water and charged into a column containing 40 ml. of
Amberlite CG-50 (NH4 ). The column was washed with 80
ml. of water and eluted with 200 ml. of 0.9~ ammonia-
water collecting 4 ml. fractions. Fractions No. ~2-34
glving positive ninhydrin were collected and concentrated
to dryness under reduced pressure to yield 141 mg. of
0-methylnegamycin as a crude powder. The crude powder
was charged into a column of silica gel (14 g.) and
developed with n-butanol-ethanol-chloroform-17~ ammonia
in water (4:5:2:3 by volume) collecting 4 ml. fractions.
Fractions No. 24-28 having positive ninhydrin reaction
and antibacterial activity versus E. coli K-12 were
combined and concentrated to dryness under reduced pres-
sure to yield 30 mg. of 0-methylnegamycin as a white
powder. 13~ yield.
_21
3~L75
E~AMPIE 4
(a) .Synthesis of Dl-N-benzyloxycarbonylnegamycin
Methyl Ester: -
To a solution containing 6 g. (11.6 mmoles) of
di-N-benzyloxycarbonylnegamycln which was obtained in
Example 3 (a), in 120 ml. of methanol, 1.5~ diazomethane-
ethanol-ether solution was added until the yellow color
of the mixture remained. After stirring for 45 minutes
the reaction mixture was concentrated to dryness under `~
reduced pressure to yeild 5.98 g of di-N-benzyloxycar-
bonylnegamycin methyl ester. d.p. 107-112 C., ~a]26 =
~4.0 (c 5.0, CH30H), 97~ yield. ?
(b) Synthesis of Deoxynegamycin:
To a solution containing 5.98 g. (11.3 mmoles)
of dl-N-benzyloxycarbonylnegamycin methyl ester which
was obtained in Example 4 (a), in 150 ml. of pyridine a
solution containg 6.4~ g. (56.4 mmoles) of methanesul-
~onyl chloride in 150 ml. of pyridine was added with ice-
cooling for 15 minutes. After stirring at room tempera-
-ture for 5 hours the reaction mixture was diluted with
150 ml. of ice water and extracted with 240 ml. of
chloroform. m e chloroform layer was washed successively
with 60 ml. portions of 0.5M sodium bisulfite, water,
lM sodium bicarbonate and water. After dehydration with
anhydrous sodium sulfate the chloro~orm solution was ;
concentrated to dryness under reduced pressure ylelding
6 17 g. (10.1 mmoles) of di-N-benzyloxycarbonyl-0-
methanesulfonylnegamycin methyl ester as a pale yellow
powder.
To a solution containing 4.9 g. (8.1 mmoles)
'
-22- ~
... . . . . . . . . .. . .
1~383~
of the pale yellow powder so obtained in 225 ml. of
acetone, 7.2 g. (48 mmoles) of sodium iodide, which
was thoroughly dried at 50-60 C. overnight, was added.
The mixture was refluxed at 65 C. for 15 hours, diluted
wi.th 1,120 ml. of water and extracted with 1,350 ml. of
ethyl acetate. The ethyl acetate layer was washed with
450 ml. of water, dehydrated with anhydrous sodium
sulfate and concentrated to dryness under reduced
pressure to yield 3.98 g. of a pale yellow powder.
The powder was subjected to a column chromatography
on silica gel (400 g.) using benzene-methyl ethyl ketone
(1:1 by volume) as the developing solvent. The eluate
was collected in 18 ml. fractions and Fractions No. 77-
170 were combined and concentrated to dryness under
reduced pressure to yield l.~ g~ (2 mmoles) of ~-iodo-
derivative (a mlxture of 2 kinds of stereoisomer). 22
yield.
To a solution containing 9~7 mg. (1.46 mmoles)
of the ~-iodo-derivative thus obtained in 20 ml. of
methanol and 8 ml. of water, lO g. of 5~ palladium- -
barium carbonate was added at room temperature under
stirring and introduction of hydrogen gas to carry out
simu1taneously dehalogenation and removal of benzyloxy-
carbonyl groups. The catalyst was removed by filtra-
tion and the filtrate was concentrated to dryness
under reduced pressure. The residue was dissolved in
16 ml. of water, adjusted to p~ 9 2-9.4 with 5N
ammonia-water and charged into a column containing 97
ml. of Amberlite CG-50 (NH4 ). After washing with -
water the column was eluted with 650 ml. of 0.2
ammonia-water and the eluate was collected in 5 ml.
~3_
~083~'75
fractions, Fractions No. 20-50 having antibacterial
activity versus E. coli K-12 and positive ninh~drin
reaction were combined and concentrated to dryness
under reduced pressure to yield g5 mg. of deoxynega-
mycin as a white powder, 28~ yield.
24 _
